For example, since TAAs like survivin and MAGE-A10 are nuclear localized in a variety of cancer types [12], [13], chemotherapy that augments the cross presentation of these antigens might boost the efficacy of survivin or MAGE-A10 vaccines. The gene discussed is BIRC5; the disease is cancer.